We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock

Delisted

NBSE was delisted on the 10th of May, 2024.

50 hedge funds and large institutions have $12.8M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

4% less funds holding

Funds holding: 5250 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

44% less capital invested

Capital invested by funds: $22.9M → $12.8M (-$10M)

75% less call options, than puts

Call options by funds: $307K | Put options by funds: $1.24M

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
9
Reduced
9
Closed
10
Calls
$307K
Puts
$1.24M
Net Calls
-$934K
Net Calls Change
-$2.63M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
51
Baker Bros. Advisors
New York
-$2.27M -926 Closed
PP
52
PDT Partners
New York
-$270K -110 Closed
Balyasny Asset Management
53
Balyasny Asset Management
Illinois
-$172K -70 Closed
OAM
54
Oxford Asset Management
United Kingdom
-$161K -66 Closed
JMPWA
55
JP Morgan Private Wealth Advisors
California
-$160K -65 Closed
EWM
56
Edge Wealth Management
New York
-$148K -60 Closed
BHA
57
Beech Hill Advisors
New York
-$104K -42 Closed
Simplex Trading
58
Simplex Trading
Illinois
-$19.9K -14 Closed
WA
59
WFG Advisors
Texas
-$6K -3 Closed
IA
60
IFP Advisors
Florida
-$5K -2 Closed
Citigroup
61
Citigroup
New York
-$1K

NBSE Hedge Fund Activity: Q1 2016 in Review

50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2016, worth a combined $12.8M — down 44% from $22.9M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NBSE and 8 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.3M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.27M sold.

  • 50 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2016, down from 52 in Q4 2015.
  • Funds reported $12.8M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2016, down 44% quarter-over-quarter.
  • 8 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2016 and 10 closed out, a net change of -2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2016 was Opaleye Management, an estimated $1.3M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2016 was Baker Bros. Advisors, an estimated $2.27M sold.

Based on aggregated 13F filings for Q1 2016.